[go: up one dir, main page]

EP0835318A2 - Vaccins contre l'hepatite c - Google Patents

Vaccins contre l'hepatite c

Info

Publication number
EP0835318A2
EP0835318A2 EP96922029A EP96922029A EP0835318A2 EP 0835318 A2 EP0835318 A2 EP 0835318A2 EP 96922029 A EP96922029 A EP 96922029A EP 96922029 A EP96922029 A EP 96922029A EP 0835318 A2 EP0835318 A2 EP 0835318A2
Authority
EP
European Patent Office
Prior art keywords
protein
immunogenic derivative
composition according
oil
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96922029A
Other languages
German (de)
English (en)
Inventor
Teresa SmithKline Beecham CABEZON SILVA
Patricia Marie SmithKline Beecham MOMIN
Nathalie Marie-Josephe Claude SmithKline GARçON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of EP0835318A2 publication Critical patent/EP0835318A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to novel vaccine formulations, to methods of their production and to their use in medicine.
  • 3 De-O-acylated monophosphoryl lipid A is known from GB2220 211 (Ribi).
  • Hepatitis C virus is described in EP-A-0 318 216.
  • a particular antigenic protein of hepatitis C virus has been designated the core protein and is described by, for example, Delisse et al., J. Hepatology, 1991;13 (Suppl. 4): S20-S23 (for genotype lb).
  • Particular envelope proteins of hepatitis C virus have been designated El and E2 and are described by, for example, Grakoui et al., 1993, J.
  • the present invention provides a vaccine composition
  • a vaccine composition comprising QS21, 3 De-O-acylated monophosphoryl lipid A (3D-MPL), an oil in water emulsion, wherein the oil in water emulsion has the following composition: a metabolisible oil, such as squalene, alpha tocopherol and tween 80, and at least one immunogen selected from the group consisting of (a) a hepatitis C virus core protein or an immunogenic derivative thereof, and (b) a hepatitis C virus envelope protein or an immunogenic derivative thereof.
  • a metabolisible oil such as squalene, alpha tocopherol and tween 80
  • an immunogen selected from the group consisting of (a) a hepatitis C virus core protein or an immunogenic derivative thereof, and (b) a hepatitis C virus envelope protein or an immunogenic derivative thereof.
  • immunogenic derivative encompasses any molecule such as a truncated or other derivative of the protein which retains the ability to induce an immune response to the protein following internal administration to a human.
  • Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
  • Immunogenic fragments of the protein which may be useful in the preparation of subunit vaccines, may be prepared by expression of the appropriate gene fragments or by peptide synthesis, for example using the Merrifield synthesis (The Peptides, Vol 2., Academic Press, NY, page 3).
  • the immunogenic derivative of the invention can be a hybrid, that is, a fusion polypeptide containing additional sequences which can carry one or more epitopes for other immunogens.
  • the immunogenic derivative of the invention can be fused to a carrier polypeptide or to another carrier which has immunostimulating properties, as in the case of an adjuvant, or which otherwise enhances the immune response to the protein or derivative thereof, or which is useful in expressing, purifying or formulating the protein or derivative thereof.
  • the invention also extends to the HCV protein or immunogenic derivative thereof when chemically conjugated to a macromolecule using a conventional linking agent such as glutaraldehyde (Geerlings et al, (1988) J, Immunol. Methods, ___, 239-244).
  • a conventional linking agent such as glutaraldehyde (Geerlings et al, (1988) J, Immunol. Methods, ___, 239-244).
  • Proteins and their immunogenic derivatives suitable for use in the present invention can be prepared by expressing DNA encoding said protein or derivative thereof in a recombinant host cell and recovering the product, and thereafter, optionally, preparing a derivative thereof.
  • a DNA molecule comprising such coding sequence can be synthesized by standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts _i _l in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by in vitro enzymatic polymerization, or by a combination of these techniques.
  • Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50ml or less.
  • Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01M MgCl2, 0.01M dithiothreitol, lmM spermidine, lmM ATP and 0.
  • lmg ml bovine serum albumin at a temperature of 4°C to ambient, generally in a volume of 50ml or less.
  • the chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C.
  • DNA polymers which encode mutants may be prepared by site-directed mutagenesis by conventional methods such as those described by G. Winter £ al in Nature 1982, 2__, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., __, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter ei ai in Biochem. Soc. Trans., 1984, 2, 224-225.
  • a protein or immunogenic derivative for use in the present invention can be prepared using the following steps: i) preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said protein or an immunogenic derivative thereof;
  • transformation is used herein to mean the introduction of foreign DNA into a host cell by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and AJ. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988.
  • conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and AJ. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988.
  • the replicable expression vector may be prepared by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment encode the desired product, under ligating conditions.
  • the DNA polymer may be preformed or formed during the construction of the vector, as desired.
  • the preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ei al cited above.
  • the recombinant host cell is prepared by transforming a host cell with a replicable expression vector under transforming conditions. Suitable transforming conditions are conventional and are described in, for example,
  • the choice of transforming conditions is determined by the host cell.
  • a bacterial host such as E. ___ may be treated with a solution of CaCl2 (Cohen ei aL Proc. Nat. Acad. Sci., 1973, _9, 2110) or with a solution comprising a mixture of RbCl, MnC-2, potassium acetate and glycerol, and then with 3- [N-morpholino] -propane-sulphonic acid, RbCl and glycerol.
  • Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells. Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis ei al and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C. The product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as E. _ ⁇ _i it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or from cell free extracts. Conventional protein isolation techniques include selective precipitation, absorption chromatography, and affinity chromatography including a monoclonal antibody affinity column.
  • the host cell is E. coli.
  • a particular aspect of the present invention provides a novel compound which comprises an HCV core protein, or an immunogenic derivative thereof, fused to a polypeptide containing foreign epitopes.
  • the polypeptide is preferably an influenza protein, such as the NS1 protein, or an immunogenic derivative thereof.
  • the vaccines of the present invention are preferential stimulators of IgG2a production and THl cell response. This is advantageous, because of the known implication of THj response in cell mediated response. Indeed in mice induction of IgG2a is correlated with such an immune response.
  • the vaccines of the invention enhance induction of cytolytic T lymphocyte responses. Induction of CTL is easily seen when the target antigen is synthesised intracellularly, ie during infection by the virus, because peptides generated by proteolytic breakdown of the antigen can enter the appropriate processing pathway, leading to presentation in association with class I molecules on the cell membrane. However, in general, pre-formed soluble antigen does not reach this processing and presentation pathway, and does not elicit class I restricted CTL.
  • the combination of 3D-MPL and QS21 together with an oil in water emulsion have been able to synergistically enhance interferon ⁇ production.
  • the oil in water emulsion may contain span 85 and/or lecithin.
  • a preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in
  • a vaccine as herein described for use in medicine.
  • the ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1 : 5 to 5 : 1 and often substantially 1 : 1.
  • the preferred range for optimal synergy is 2.5:1 to 1:1 3D MPL: QS21.
  • QS21 and 3D MPL will be present in a vaccine in the range 1 ⁇ g - 100 ⁇ g, preferably 10 ⁇ g - 50 ⁇ g per dose.
  • the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80.
  • the ratio of squalene: alpha tocopherol is equal or less than 1 as this provides a more stable emulsion.
  • Span 85 may also be present at a level of 1%.
  • the vaccines of the present invention will further contain a stabiliser.
  • Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland,
  • each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 2-100 ⁇ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • formulations of the present invention may be used for both prophylatic and therapeutic purposes.
  • the invention provides a method of treatment comprising administering an effective amount of a vaccine of the present invention to a patient.
  • Plasmid pMG81 a derivative of pMG27 (Gross et al 1985, Mol.Cell. Biol. 5: 1015) in which: (i) the 81 first codons of the NS1 coding region from influenza strain A/PR/8/34 cleaved from plasmid pASlEH/801 (Young et al. 1983, Proc. Natl. Acad. Sci. 80: 6105) have been inserted downstream of the pL promoter and ii) the ampicillin resistance gene has been replaced by the kanamycin resistance gene from transposon Tn902, was used to express the fusion protein NSl-Core.
  • HCV genomic sequences of hepatitis C virus genotype lb (Delisse et al, 1991 J. Hepathology 13, suppl. 4:S20-23) were PCR amplified and cloned into pUC12 plasmid to give plasmid TCM 128-2.
  • nucleotides sequences corresponding to amino acids 2-166 of the core protein were amplified from TCM 128-2.
  • Ncol and Xbal restriction sites have been generated at the 5' and 3' ends of the core sequences allowing insertion into the same sites of plasmid pMG81 to give pRTT 14129.
  • pRJT 14129 contains the coding sequence for the fusion protein NS1 (flu)-core(HCV) and expresses the polypeptide described in SEQ ID NO. 1.
  • the coding sequence for the fusion protein NS1 (flu)-core(HCV) is contained in SEQ ID NO 2.
  • SEQ ID NO 3 shows the amino acid sequence 1-1006 of HCV genome type la (H).
  • Plasmid pRIT14129 was introduced into E. coli AR 58 (Mott et al, 1985, Proc, Natl. Acad. Sci., 82:88) containing the thermosensitive repressor of the ⁇ pL promoter.
  • the recombinant bacteria were grown in a 20 Litters fermentor under fed-batch conditions at 30°.
  • the expression of the NSl-Core protein was induced by raising the temperature to 38-42°C.
  • the cells were then harvested and mechanically disrupted.
  • Step 1 Bacterial cells were broken (Rannie-2 x 14,500 pi) in a 20 mM phosphate buffer pH7 containing protease inhibitors (lmM pefabloc, 0.5mg leupeptin, 0.1% aprotinin).
  • Step 2 Lysate was centrifuged for 25 minutes, at 17,000g. At this stage the recombinant protein was insoluble and was recovered in the pellet The pellet was washed two times with lOmM phosphate pH6.8, 2M NaCl, 4M urea; three times with lOmM phosphate pH 6.8, 0.15M NaCl, and centrifuged at 17,000g for 25 minutes after each wash step. These steps were introduced in order to lower the endotoxin content of the purified product.
  • Step 3 The washed pellets re suspended in SDS-PAGE reducing sample buffer, boiled for 5 minutes, centrifuged again at 27,000g for 25 minutes and then applied on a 12% polyacrylamide gel for separation of the remaining proteins (Prep Cell equipment Biorad).
  • Step 4 The protein was electroluted from the gels in 25mM Tris pH8, 200mM glycine, 0.1% SDS; precipitated by 10% TCA at 0° and finally resuspended in lOmM phosphate pH 6.8, 150mM NaCl, 50mM sarcosyl.
  • the purified antigen appears as a doublet, in the 27-30 kD range, both bands are recognised by an anti-NSl monoclonal antibody as well as by anti-core specific human monoclonal and rabbit polyclonal antibodies.
  • the two adjuvant formulations were made each comprising the following oil in water emulsion component
  • SB26 5% squalene 5% tocopherol 0.4% tween 80; the particle size was 500 nm size SB62: 5% Squalene 5% tocopherol 2.0% tween 80; the particle size was 180 nm
  • Tween 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS.
  • PBS phosphate buffered saline
  • 5g of DL alpha tocopherol and 5ml of squalene are vortexed to mix thoroughly.
  • 90ml of PBS Tween solution is added and mixed thoroughly.
  • the resulting emulsion is then passed through a syringe and finally microfluidised by using an Ml 10S microfluidics machine.
  • the resulting oil droplets have a size of approximately 180 nm.
  • This emulsion was prepared in an analogous manner utilising 0.4% tween 80.
  • Oligomeric forms of E1-E2 HCV envelope proteins can be prepared form mammalian cells infected with recombinant vaccinia virus expressing HCV envelope sequences as a polyprotein.
  • the coding sequences for a polyprotein covering the amino acids 167- 1006 of HCV genome of type la (H) can be inserted in vaccinia virus vectors using procedures known in the art and the resulting plasmid used to prepared vaccinia recombinant virus that will lead to expression of the polyprotein in infected cells.
  • the expressed polyprotein is processed and retained intracellularly.
  • E1-E2 oligomeric form can be purified from cell extracts in which the E1/E2 protein complex has been solubilized using specific detergent (Ralston et al, 1993, J. Virology 67:6753) (Dubuisson et al 1994, J. Virology 68:6147).
  • Formulations of oligomeric E1E2 are prepared analagously to the formulations of Example 1.
  • Example 3 Formulations of oligomeric E1E2 are prepared analagously to the formulations of Example 1.
  • Formulations containing both the fusion protein of Example 1 and the E1E2 oligomer of Example 2 are prepared analagously to the formulations of Example 1, each formulation containing between 50 and lOO ⁇ g of each protein.
  • SEQ ID NO 2 1 GAATTCGTAC CTAGATCTCT CACCTACCAA ACAATGCCCC CCTGCAAAAA
  • ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA 4501 GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC TGCAGGTCGA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne un composition de vaccin comprenant: du QS21, un lipide A de monophosphoryle 3 De-O-acétylé (3D-MPL); une émulsion d'huile dans l'eau, l'huile possédant la composition suivante: une huile métabolisable tel que du squalène, du tocophérol alpha et du Tween 80; et, enfin, au moins un immunogène choisi dans le groupe comprenant (a) une protéine de noyau du virus de l'hépatite C ou un de ses dérivés immunogènes, et (b) une protéine d'enveloppe du virus de l'hépatite C ou un de ses dérivés immunogènes.
EP96922029A 1995-06-29 1996-06-20 Vaccins contre l'hepatite c Withdrawn EP0835318A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9513261 1995-06-29
GBGB9513261.9A GB9513261D0 (en) 1995-06-29 1995-06-29 Vaccines
PCT/EP1996/002764 WO1997001640A2 (fr) 1995-06-29 1996-06-20 Vaccins contre l'hepatite c

Publications (1)

Publication Number Publication Date
EP0835318A2 true EP0835318A2 (fr) 1998-04-15

Family

ID=10776867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96922029A Withdrawn EP0835318A2 (fr) 1995-06-29 1996-06-20 Vaccins contre l'hepatite c

Country Status (15)

Country Link
EP (1) EP0835318A2 (fr)
JP (1) JPH11508769A (fr)
KR (1) KR19990028505A (fr)
AU (1) AU6304996A (fr)
BR (1) BR9609258A (fr)
CA (1) CA2222456A1 (fr)
CZ (1) CZ422397A3 (fr)
GB (1) GB9513261D0 (fr)
HU (1) HUP9901901A3 (fr)
IL (1) IL122589A0 (fr)
NO (1) NO976060L (fr)
PL (1) PL324906A1 (fr)
TR (1) TR199701713T1 (fr)
WO (1) WO1997001640A2 (fr)
ZA (1) ZA965459B (fr)

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028656A2 (fr) 2001-10-03 2003-04-10 Chiron Corporation Compositions d'adjuvants
WO2003070909A2 (fr) 2002-02-20 2003-08-28 Chiron Corporation Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
WO2006086799A2 (fr) 2005-02-11 2006-08-17 Novartis Vaccines And Diagnostics Inc. Reactifs de peptide specifiques au prion
WO2008020335A2 (fr) 2006-06-09 2008-02-21 Novartis Ag Compositions immunogènes pour streptococcus agalactiae
WO2009034473A2 (fr) 2007-09-12 2009-03-19 Novartis Ag Antigènes mutants gas57 et anticorps gas57
EP2108374A1 (fr) 2004-04-30 2009-10-14 Novartis Vaccines and Diagnostics S.r.l. Conjugués meningococciques combinés presentant une protéine porteuse commune
EP2168597A1 (fr) 2001-07-26 2010-03-31 Novartis Vaccines and Diagnostics S.r.l. Vaccins comportant des adjuvants d'aluminium et de l'histidine
EP2179729A1 (fr) 2003-06-02 2010-04-28 Novartis Vaccines and Diagnostics, Inc. Compositions immunogene sur la base de microparticules contenant un toxoide adsorbant et un antigene contenant un polysaccharide
EP2193810A1 (fr) 2005-01-14 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Vaccin conjugué contre le meningocoque
WO2010067286A2 (fr) 2008-12-09 2010-06-17 Pfizer Vaccines Llc Vaccin peptidique ige ch3
WO2010079464A1 (fr) 2009-01-12 2010-07-15 Novartis Ag Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
WO2010100632A2 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigènes de chlamydia
WO2010125480A1 (fr) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Vaccin anti-pneumococcique et ses utilisations
EP2258388A1 (fr) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Vésicules de membrane externe bactérienne améliorées
EP2258716A2 (fr) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Variantes multiples de protéine NMB1870 de la méningococcie
EP2258365A1 (fr) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour potentialiser l'immunité
EP2263688A1 (fr) 2001-06-20 2010-12-22 Novartis AG Vaccins combinés contre Neisseria meningitidis
WO2010146414A1 (fr) 2009-06-15 2010-12-23 National University Of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
EP2267036A1 (fr) 2003-10-02 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Saccharides capsulaires de méningococcie hypo et hyperacétylés
EP2267005A1 (fr) 2003-04-09 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Toxine ADP-ribosylante de Listeria monocytogenes
EP2272531A2 (fr) 2004-04-30 2011-01-12 Novartis Vaccines and Diagnostics S.r.l. Intégration du vaccin conjugué de méningococcus
WO2011004263A2 (fr) 2009-07-07 2011-01-13 Novartis Ag Immunogènes d' escherichia coli conservés
WO2011007257A1 (fr) 2009-07-16 2011-01-20 Novartis Ag Immunogènes d'escherichia coli détoxifiés
EP2277894A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277538A1 (fr) 2003-10-02 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Vaccins combinés contre la méningite
EP2277595A2 (fr) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Composés pour potentialiser l'immunité
EP2279747A1 (fr) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Vésicules bactériennes immunogènes dotées de protéines de membrane externe
EP2279746A2 (fr) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
WO2011013034A1 (fr) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Peptides tau antigéniques et leurs utilisations
EP2289546A2 (fr) 2003-01-30 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Vaccins injectables contre les multiples serogroupes du meningocoque
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
WO2011027257A2 (fr) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Vaccin pcsk9
WO2011030218A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Vaccins combinés contre les maladies des voies respiratoires
EP2298795A1 (fr) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogènes d'E. coli uropathogène
EP2302039A1 (fr) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Particules de type virus comprenant le polypeptide gag de HML-2
WO2011036562A1 (fr) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Purification de vésicules bactériennes
WO2011036564A2 (fr) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Souches de shigella à hyperblebs
WO2011039631A2 (fr) 2009-09-30 2011-04-07 Novartis Ag Expression de polypeptides fhbp méningococciques
WO2011048561A1 (fr) 2009-10-20 2011-04-28 Novartis Ag Procédés diagnostiques et thérapeutiques pour une maladie cardiaque rhumatismale basés sur des marqueurs de streptocoque de groupe a
WO2011051893A1 (fr) 2009-10-27 2011-05-05 Novartis Ag Polypeptides fhbp méningococciques modifiés
WO2011058302A1 (fr) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Antigène associé à la bactériémie à partir de staphylococcus aureus
EP2327719A1 (fr) 2001-09-06 2011-06-01 Novartis Vaccines and Diagnostics S.r.l. Adhésines de Meningococcus
WO2011077309A2 (fr) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Compositions de vaccin
EP2341069A1 (fr) 2004-05-14 2011-07-06 Novartis Vaccines and Diagnostics S.r.l. Polypeptides de haemophilus influenzae non typable
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
EP2351772A1 (fr) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Protéines et acides nucléiques d'Escherichia coli associé à la méningite/sepsie
EP2351579A1 (fr) 2002-10-11 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
EP2357184A1 (fr) 2006-03-23 2011-08-17 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
EP2360175A2 (fr) 2005-11-22 2011-08-24 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (VLPs) de norovirus et de sapovirus
WO2011104632A1 (fr) 2010-02-26 2011-09-01 Novartis Ag Protéines et compositions immunogènes
WO2011121576A2 (fr) 2010-04-01 2011-10-06 Novartis Ag Protéines et compositions immunogènes
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
EP2385127A1 (fr) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Polypeptides tandem, hybrides et chimères de NMB1870 de méningocoque
WO2011138636A1 (fr) 2009-09-30 2011-11-10 Novartis Ag Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
WO2011149564A1 (fr) 2010-05-28 2011-12-01 Tetris Online, Inc. Infrastructure de jeu informatique asynchrone hybride interactif
WO2011154863A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
WO2011154878A1 (fr) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
WO2011161551A2 (fr) 2010-06-11 2011-12-29 Novartis Ag Vaccins à base de vésicules membranaires
WO2012006359A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Délivrance d'arn auto-répliquant en utilisant des particules polymères biodégradables
WO2012006293A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Compositions immunogènes dérivées d'un norovirus et méthodes
WO2012035519A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Compositions immunogènes
EP2433647A2 (fr) 2005-01-27 2012-03-28 Children's Hospital & Research Center at Oakland Vaccins à vésicule à base de GNA1870 pour protection spectrale élargie contre les maladies causées par Neisseria Meningitidis
WO2012049662A1 (fr) 2010-10-15 2012-04-19 Novartis Vaccines Institute For Global Health Srl Souches hyper bourgeonnantes de salmonella
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
EP2510947A1 (fr) 2009-04-14 2012-10-17 Novartis AG Compositions pour l'immunisation contre le staphylococcus aureus
EP2537857A2 (fr) 2007-12-21 2012-12-26 Novartis AG Formes mutantes de streptolysine O
WO2013016460A1 (fr) 2011-07-25 2013-01-31 Novartis Ag Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
WO2013030783A1 (fr) 2011-08-30 2013-03-07 Novartis Ag Protéines et compositions immunogènes
WO2013038385A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Combinaison de vaccin contre escherichia coli
WO2013038375A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Procédés de production de glycoconjugués de saccharide-protéine
EP2572726A1 (fr) 2007-08-01 2013-03-27 Novartis AG Compositions comprenant des antigènes pneumocoques
EP2583678A2 (fr) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Immunopotentiateurs de petites molécules et dosages pour leur détection
EP2586790A2 (fr) 2006-08-16 2013-05-01 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
WO2013084071A2 (fr) 2011-12-08 2013-06-13 Novartis Ag Vaccin à base de toxines de clostridium difficile
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
EP2631245A1 (fr) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Protéines chimères de liaison du facteur H contenant un domaine B hétérologue, et procédés d utilisation associés
WO2013124473A1 (fr) 2012-02-24 2013-08-29 Novartis Ag Protéines de pilus et compositions
WO2013160335A2 (fr) 2012-04-26 2013-10-31 Novartis Ag Antigènes et combinaisons d'antigènes
EP2659906A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659912A2 (fr) 2007-07-17 2013-11-06 Novartis AG Purification de conjugué
EP2659908A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013164754A2 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
WO2013174832A1 (fr) 2012-05-22 2013-11-28 Novartis Ag Conjugué de sérogroupe x de méningocoque
WO2014053612A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Composition immunogène
WO2014053521A2 (fr) 2012-10-02 2014-04-10 Novartis Ag Conjugués saccharidiques non linéaires
EP2811027A1 (fr) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le VRS et le PIV
EP2886551A2 (fr) 2008-02-21 2015-06-24 Novartis AG Polypeptides fHbp méningococciques
EP2891498A1 (fr) 2007-12-20 2015-07-08 Novartis AG Procédés de fermentation pour cultiver des streptocoques et procédés de purification pour obtenir des CPS à partir de ceux-ci
WO2015110941A2 (fr) 2014-01-21 2015-07-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2015123291A1 (fr) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
WO2016113644A1 (fr) 2015-01-15 2016-07-21 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins antipneumococciques
WO2016193405A1 (fr) 2015-06-03 2016-12-08 Affiris Ag Vaccins d'il-23-p19
WO2017005851A1 (fr) 2015-07-07 2017-01-12 Affiris Ag Vaccins pour le traitement et la prévention de maladies médiées par ige
WO2017013548A1 (fr) 2015-07-21 2017-01-26 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
WO2017085586A1 (fr) 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
WO2017125844A1 (fr) 2016-01-19 2017-07-27 Pfizer Inc. Vaccins anticancéreux
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
EP3327028A1 (fr) 2010-03-30 2018-05-30 Children's Hospital & Research Center at Oakland Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
EP3345617A1 (fr) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Antigènes de pseudomonas et combinaisons d'antigènes
WO2018134693A1 (fr) 2017-01-20 2018-07-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP3498302A1 (fr) 2005-02-01 2019-06-19 Novartis Vaccines and Diagnostics S.r.l. Conjugaison de saccharides capsulaires streptococciques
WO2020039033A1 (fr) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Protéines et compositions immunogènes
WO2020039359A2 (fr) 2018-08-24 2020-02-27 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
WO2020121159A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
EP3689375A1 (fr) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta Vaccins contre le vhc e1e2 et procédés d'utilisation desdits vaccins
WO2020170190A1 (fr) 2019-02-22 2020-08-27 Pfizer Inc. Procédés de purification de polysaccharides bactériens
WO2020208502A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués, kits les comprenant et leurs utilisations
WO2021084429A1 (fr) 2019-11-01 2021-05-06 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
WO2021165928A2 (fr) 2020-02-23 2021-08-26 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
WO2021165847A1 (fr) 2020-02-21 2021-08-26 Pfizer Inc. Purification de saccharides
NL2027383A (en) 2020-01-24 2021-09-01 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2022090893A2 (fr) 2020-10-27 2022-05-05 Pfizer Inc. Compositions d'escherichia coli et procédés associés
WO2022097010A1 (fr) 2020-11-04 2022-05-12 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
WO2022101745A2 (fr) 2020-11-10 2022-05-19 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2022137078A1 (fr) 2020-12-23 2022-06-30 Pfizer Inc. Mutants fimh e. coli et leurs utilisations
WO2022147373A1 (fr) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
WO2022178196A1 (fr) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant méningococcique b
EP4074726A2 (fr) 2014-07-23 2022-10-19 Children's Hospital & Research Center at Oakland Variants de protéines de liaison au facteur h et leurs procédés d'utilisation
WO2022249107A2 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2022249106A2 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2023092090A1 (fr) 2021-11-18 2023-05-25 Matrivax, Inc. Compositions de protéines de fusion immunogènes et leurs procédés d'utilisation
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024110839A2 (fr) 2022-11-22 2024-05-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
US12018063B2 (en) 2020-02-26 2024-06-25 Versitech Limited PD-1-based vaccines against coronavirus infection
WO2024166008A1 (fr) 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024201324A2 (fr) 2023-03-30 2024-10-03 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
WO2024214016A1 (fr) 2023-04-14 2024-10-17 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
US12156910B2 (en) 2018-11-16 2024-12-03 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
EP4480544A2 (fr) 2015-08-25 2024-12-25 Babita Agrawal Compositions immunomodulatrices et leurs procédés d'utilisation
EP4491735A2 (fr) 2015-10-08 2025-01-15 The Governors of the University of Alberta Hétérodimères e1/e2 du virus de l'hépatite c et leurs procédés de production

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (fr) 1996-01-04 1997-07-17 Rican Limited Bacterioferritine de helicobacter pilori
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO2000011186A1 (fr) * 1998-08-21 2000-03-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins contenant un peptide modifie du vhc
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
CA2391843C (fr) * 1999-11-19 2011-10-18 Csl Limited Compositions vaccinales contre le vhc
US20050130125A1 (en) * 2002-03-04 2005-06-16 Yuly Zagyansky End of aids for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end
PH12012500477A1 (en) * 2009-09-10 2012-10-22 Merial Inc New vaccine formulations comprising saponin-containing adjuvants
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2821995C (fr) 2011-01-06 2019-02-12 Bionor Immuno As Peptides monomeres et multimeres immunogenes contre le vih
WO2013182661A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Peptides issus de protéines virales pour l'utilisation en tant qu'immunogènes et réactifs de dosage
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2021160887A1 (fr) 2020-02-14 2021-08-19 Immunor As Vaccin contre le coronavirus
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049679C (fr) * 1990-08-24 2005-06-21 Sushil G. Devare Recherche des anticorps de l'hepatite c a l'aide d'antigenes recombinants
DE4041304A1 (de) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw Von strukturproteinen des hepatitis c-virus abgeleitete polypeptide, testkits, die diese polypeptide enthalten und impfstoffe gegen infektionen von hepatitis c-viren
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
DK0761231T3 (da) * 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk ＨＢｃ融合蛋白粒子およびその製造方法
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9701640A2 *

Cited By (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2896629A1 (fr) 2000-10-27 2015-07-22 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines de streptocoques des groupes A et B
EP2277894A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2284182A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2284183A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277895A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2284181A1 (fr) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2277896A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
EP2336368A1 (fr) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène à régulation positive dans le cancer de la prostate
EP2339035A1 (fr) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène régulé en hausse dans le cancer de la prostate
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
EP2277537A2 (fr) 2001-06-20 2011-01-26 Novartis AG Vaccin conjugué combiné contre Neisseria meningitidis
EP2277539A2 (fr) 2001-06-20 2011-01-26 Novartis AG Vaccin conjugué combiné contre Neisseria meningitidis
EP2263688A1 (fr) 2001-06-20 2010-12-22 Novartis AG Vaccins combinés contre Neisseria meningitidis
EP2277536A2 (fr) 2001-06-20 2011-01-26 Novartis AG Purification de polysaccharides capsulaires bactériens
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP2168597A1 (fr) 2001-07-26 2010-03-31 Novartis Vaccines and Diagnostics S.r.l. Vaccins comportant des adjuvants d'aluminium et de l'histidine
EP2255827A1 (fr) 2001-07-26 2010-12-01 Novartis Vaccines and Diagnostics S.r.l. Vaccins comportant des adjuvants d'aluminium et de l'histidine
EP2266605A1 (fr) 2001-07-26 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Vaccins comportant des adjuvants d'aluminium et de l'histidine
EP2360176A2 (fr) 2001-09-06 2011-08-24 Novartis Vaccines and Diagnostics S.r.l. Hybride et tandem l'expression des protéines de Neisseria
EP2829549A2 (fr) 2001-09-06 2015-01-28 Novartis Vaccines and Diagnostics S.r.l. Expression tandem et hybride de protéines de Neisserial
EP2327719A1 (fr) 2001-09-06 2011-06-01 Novartis Vaccines and Diagnostics S.r.l. Adhésines de Meningococcus
WO2003028656A2 (fr) 2001-10-03 2003-04-10 Chiron Corporation Compositions d'adjuvants
EP2572707A2 (fr) 2002-02-20 2013-03-27 Novartis Vaccines and Diagnostics, Inc. Microparticules avec des molécules contenant un polypeptide adsorbé
WO2003070909A2 (fr) 2002-02-20 2003-08-28 Chiron Corporation Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
EP2302039A1 (fr) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Particules de type virus comprenant le polypeptide gag de HML-2
EP2258388A1 (fr) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Vésicules de membrane externe bactérienne améliorées
EP2258389A1 (fr) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Vésicules de membrane externe bactérienne améliorées
EP2258390A1 (fr) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Vésicules de membrane externe bactérienne améliorées
EP2351579A1 (fr) 2002-10-11 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
EP2353608A1 (fr) 2002-10-11 2011-08-10 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
EP2279746A2 (fr) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
EP2258716A2 (fr) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Variantes multiples de protéine NMB1870 de la méningococcie
EP2261239A2 (fr) 2002-11-22 2010-12-15 Novartis Vaccines and Diagnostics S.r.l. Variants multiples de la protéine NMB1870 meningococcique
EP2258717A2 (fr) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Formes variantes du NadA de la méningococcie
EP2289546A2 (fr) 2003-01-30 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Vaccins injectables contre les multiples serogroupes du meningocoque
EP2258365A1 (fr) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour potentialiser l'immunité
EP2267005A1 (fr) 2003-04-09 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Toxine ADP-ribosylante de Listeria monocytogenes
EP2179729A1 (fr) 2003-06-02 2010-04-28 Novartis Vaccines and Diagnostics, Inc. Compositions immunogene sur la base de microparticules contenant un toxoide adsorbant et un antigene contenant un polysaccharide
EP2277538A1 (fr) 2003-10-02 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Vaccins combinés contre la méningite
EP2267036A1 (fr) 2003-10-02 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Saccharides capsulaires de méningococcie hypo et hyperacétylés
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
EP2272531A2 (fr) 2004-04-30 2011-01-12 Novartis Vaccines and Diagnostics S.r.l. Intégration du vaccin conjugué de méningococcus
EP2108374A1 (fr) 2004-04-30 2009-10-14 Novartis Vaccines and Diagnostics S.r.l. Conjugués meningococciques combinés presentant une protéine porteuse commune
EP2341069A1 (fr) 2004-05-14 2011-07-06 Novartis Vaccines and Diagnostics S.r.l. Polypeptides de haemophilus influenzae non typable
EP2351774A1 (fr) 2004-05-14 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptides de hamophilus influenzae non typable
EP2351773A1 (fr) 2004-05-14 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptides de haemophilus influenzae non typable
EP2343313A1 (fr) 2004-05-14 2011-07-13 Novartis Vaccines and Diagnostics S.r.l. Polypeptides de hamophilus influenzae non typable
EP2848692A1 (fr) 2004-05-21 2015-03-18 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'alphavirus de vaccins contre le virus de la grippe
EP2811027A1 (fr) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le VRS et le PIV
EP2277595A2 (fr) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Composés pour potentialiser l'immunité
EP2583678A2 (fr) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Immunopotentiateurs de petites molécules et dosages pour leur détection
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
EP2279747A1 (fr) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Vésicules bactériennes immunogènes dotées de protéines de membrane externe
EP2193810A1 (fr) 2005-01-14 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Vaccin conjugué contre le meningocoque
EP2433647A2 (fr) 2005-01-27 2012-03-28 Children's Hospital & Research Center at Oakland Vaccins à vésicule à base de GNA1870 pour protection spectrale élargie contre les maladies causées par Neisseria Meningitidis
EP3498302A1 (fr) 2005-02-01 2019-06-19 Novartis Vaccines and Diagnostics S.r.l. Conjugaison de saccharides capsulaires streptococciques
WO2006086799A2 (fr) 2005-02-11 2006-08-17 Novartis Vaccines And Diagnostics Inc. Reactifs de peptide specifiques au prion
EP2298795A1 (fr) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogènes d'E. coli uropathogène
EP2351772A1 (fr) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Protéines et acides nucléiques d'Escherichia coli associé à la méningite/sepsie
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
EP2360175A2 (fr) 2005-11-22 2011-08-24 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (VLPs) de norovirus et de sapovirus
EP2385127A1 (fr) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Polypeptides tandem, hybrides et chimères de NMB1870 de méningocoque
EP2385126A1 (fr) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Polypeptides tandem, hybrides et chimères de NMB1870 de méningocoque
EP3346009A1 (fr) 2005-11-25 2018-07-11 GlaxoSmithKline Biologicals S.A. Polypeptides tandem, hybrides et chimères de nmb1870 de méningocoque
EP2357184A1 (fr) 2006-03-23 2011-08-17 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
WO2008020335A2 (fr) 2006-06-09 2008-02-21 Novartis Ag Compositions immunogènes pour streptococcus agalactiae
EP2586790A2 (fr) 2006-08-16 2013-05-01 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
EP2659912A2 (fr) 2007-07-17 2013-11-06 Novartis AG Purification de conjugué
US9463250B2 (en) 2007-07-17 2016-10-11 Glaxosmithkline Biologicals Sa Conjugate purification
EP2572726A1 (fr) 2007-08-01 2013-03-27 Novartis AG Compositions comprenant des antigènes pneumocoques
WO2009034473A2 (fr) 2007-09-12 2009-03-19 Novartis Ag Antigènes mutants gas57 et anticorps gas57
EP2891498A1 (fr) 2007-12-20 2015-07-08 Novartis AG Procédés de fermentation pour cultiver des streptocoques et procédés de purification pour obtenir des CPS à partir de ceux-ci
EP2537857A2 (fr) 2007-12-21 2012-12-26 Novartis AG Formes mutantes de streptolysine O
EP3263591A1 (fr) 2008-02-21 2018-01-03 GlaxoSmithKline Biologicals S.A. Polypeptides fhbp méningococciques
EP2886551A2 (fr) 2008-02-21 2015-06-24 Novartis AG Polypeptides fHbp méningococciques
EP2631245A1 (fr) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Protéines chimères de liaison du facteur H contenant un domaine B hétérologue, et procédés d utilisation associés
EP2865389A1 (fr) 2008-12-09 2015-04-29 Pfizer Vaccines LLC Vaccin peptidique IgE CH3
WO2010067286A2 (fr) 2008-12-09 2010-06-17 Pfizer Vaccines Llc Vaccin peptidique ige ch3
WO2010079464A1 (fr) 2009-01-12 2010-07-15 Novartis Ag Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif
WO2010100632A2 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigènes de chlamydia
EP3549602A1 (fr) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Antigènes de chlamydia
EP3263128A2 (fr) 2009-04-14 2018-01-03 GlaxoSmithKline Biologicals S.A. Compositions pour l'immunisation contre staphylococcus aureus
EP2510947A1 (fr) 2009-04-14 2012-10-17 Novartis AG Compositions pour l'immunisation contre le staphylococcus aureus
WO2010125480A1 (fr) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Vaccin anti-pneumococcique et ses utilisations
WO2010146414A1 (fr) 2009-06-15 2010-12-23 National University Of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
EP2944320A1 (fr) 2009-06-15 2015-11-18 National University of Singapore Vaccin contre la grippe, composition et procédés d'utilisation
WO2011004263A2 (fr) 2009-07-07 2011-01-13 Novartis Ag Immunogènes d' escherichia coli conservés
WO2011007257A1 (fr) 2009-07-16 2011-01-20 Novartis Ag Immunogènes d'escherichia coli détoxifiés
EP2837386A1 (fr) 2009-07-16 2015-02-18 Novartis AG Immunogènes d'escherichia coli détoxifiés
WO2011013034A1 (fr) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Peptides tau antigéniques et leurs utilisations
EP3017828A1 (fr) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
WO2011027257A2 (fr) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Vaccin pcsk9
EP2865752A1 (fr) 2009-09-03 2015-04-29 Pfizer Vaccines LLC Vaccin PCSK9
EP3358008A1 (fr) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Vaccin pcsk9
WO2011030218A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Vaccins combinés contre les maladies des voies respiratoires
WO2011036564A2 (fr) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Souches de shigella à hyperblebs
EP3279313A2 (fr) 2009-09-28 2018-02-07 GlaxoSmithKline Biologicals S.A. Souches de shigella à hyperblebs
US11339367B2 (en) 2009-09-28 2022-05-24 Glaxosmithkline Biologicals Sa Hyperblebbing Shigella strains
WO2011036562A1 (fr) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Purification de vésicules bactériennes
WO2011138636A1 (fr) 2009-09-30 2011-11-10 Novartis Ag Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
WO2011039631A2 (fr) 2009-09-30 2011-04-07 Novartis Ag Expression de polypeptides fhbp méningococciques
WO2011048561A1 (fr) 2009-10-20 2011-04-28 Novartis Ag Procédés diagnostiques et thérapeutiques pour une maladie cardiaque rhumatismale basés sur des marqueurs de streptocoque de groupe a
WO2011051893A1 (fr) 2009-10-27 2011-05-05 Novartis Ag Polypeptides fhbp méningococciques modifiés
WO2011058302A1 (fr) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Antigène associé à la bactériémie à partir de staphylococcus aureus
WO2011077309A2 (fr) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Compositions de vaccin
EP3257525A2 (fr) 2009-12-22 2017-12-20 Celldex Therapeutics, Inc. Compositions vaccinales
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
WO2011104632A1 (fr) 2010-02-26 2011-09-01 Novartis Ag Protéines et compositions immunogènes
EP3327028A1 (fr) 2010-03-30 2018-05-30 Children's Hospital & Research Center at Oakland Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
EP4036104A1 (fr) 2010-03-30 2022-08-03 Children's Hospital & Research Center at Oakland Protéines de liaison de facteur h (fhbp) avec propriétés altérées et leurs procédés d'utilisation
WO2011121576A2 (fr) 2010-04-01 2011-10-06 Novartis Ag Protéines et compositions immunogènes
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
WO2011149564A1 (fr) 2010-05-28 2011-12-01 Tetris Online, Inc. Infrastructure de jeu informatique asynchrone hybride interactif
WO2011154878A1 (fr) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
EP2942061A2 (fr) 2010-06-07 2015-11-11 Pfizer Vaccines LLC Vaccin peptidique ige ch3
WO2011154863A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
EP3399021A1 (fr) 2010-06-11 2018-11-07 GlaxoSmithKline Biologicals S.A. Vaccins d'omv
EP4219682A2 (fr) 2010-06-11 2023-08-02 GlaxoSmithKline Biologicals SA Vaccins omv
WO2011161551A2 (fr) 2010-06-11 2011-12-29 Novartis Ag Vaccins à base de vésicules membranaires
WO2012006293A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Compositions immunogènes dérivées d'un norovirus et méthodes
EP3611269A1 (fr) 2010-07-06 2020-02-19 GlaxoSmithKline Biologicals SA Administration d' arn autoreplicatif en utilisant des particules de polymères biodégradables
EP3153578A1 (fr) 2010-07-06 2017-04-12 Novartis Ag Compositions immunogènes dérivées de norovirus et procédés
WO2012006359A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Délivrance d'arn auto-répliquant en utilisant des particules polymères biodégradables
WO2012035519A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Compositions immunogènes
WO2012049662A1 (fr) 2010-10-15 2012-04-19 Novartis Vaccines Institute For Global Health Srl Souches hyper bourgeonnantes de salmonella
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
WO2013016460A1 (fr) 2011-07-25 2013-01-31 Novartis Ag Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
WO2013030783A1 (fr) 2011-08-30 2013-03-07 Novartis Ag Protéines et compositions immunogènes
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
US10105429B2 (en) 2011-09-14 2018-10-23 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
WO2013038375A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Procédés de production de glycoconjugués de saccharide-protéine
WO2013038385A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Combinaison de vaccin contre escherichia coli
WO2013084071A2 (fr) 2011-12-08 2013-06-13 Novartis Ag Vaccin à base de toxines de clostridium difficile
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
WO2013124473A1 (fr) 2012-02-24 2013-08-29 Novartis Ag Protéines de pilus et compositions
EP3804749A2 (fr) 2012-04-26 2021-04-14 GlaxoSmithKline Biologicals S.A. Antigènes et leurs combinaisons
WO2013160335A2 (fr) 2012-04-26 2013-10-31 Novartis Ag Antigènes et combinaisons d'antigènes
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659908A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP3563865A2 (fr) 2012-05-04 2019-11-06 Pfizer Inc Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin
WO2013164754A2 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin
WO2013174832A1 (fr) 2012-05-22 2013-11-28 Novartis Ag Conjugué de sérogroupe x de méningocoque
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
EP3400960A1 (fr) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Vésicules de membrane externe
EP4056198A2 (fr) 2012-09-18 2022-09-14 GlaxoSmithKline Biologicals SA Vésicules de membrane externe
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
WO2014053521A2 (fr) 2012-10-02 2014-04-10 Novartis Ag Conjugués saccharidiques non linéaires
EP3482770A1 (fr) 2012-10-03 2019-05-15 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
WO2014053612A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Composition immunogène
EP3345617A1 (fr) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Antigènes de pseudomonas et combinaisons d'antigènes
EP3689375A1 (fr) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta Vaccins contre le vhc e1e2 et procédés d'utilisation desdits vaccins
WO2015110941A2 (fr) 2014-01-21 2015-07-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
EP3607966A1 (fr) 2014-01-21 2020-02-12 Pfizer Inc Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
EP3616716A2 (fr) 2014-01-21 2020-03-04 Pfizer Inc Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2015123291A1 (fr) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
EP4074726A2 (fr) 2014-07-23 2022-10-19 Children's Hospital & Research Center at Oakland Variants de protéines de liaison au facteur h et leurs procédés d'utilisation
WO2016113644A1 (fr) 2015-01-15 2016-07-21 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins antipneumococciques
WO2016193405A1 (fr) 2015-06-03 2016-12-08 Affiris Ag Vaccins d'il-23-p19
WO2017005851A1 (fr) 2015-07-07 2017-01-12 Affiris Ag Vaccins pour le traitement et la prévention de maladies médiées par ige
WO2017013548A1 (fr) 2015-07-21 2017-01-26 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
EP4480544A2 (fr) 2015-08-25 2024-12-25 Babita Agrawal Compositions immunomodulatrices et leurs procédés d'utilisation
EP4491735A2 (fr) 2015-10-08 2025-01-15 The Governors of the University of Alberta Hétérodimères e1/e2 du virus de l'hépatite c et leurs procédés de production
WO2017085586A1 (fr) 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
EP3733201A1 (fr) 2016-01-19 2020-11-04 Pfizer Inc Vaccins contre le cancer
WO2017125844A1 (fr) 2016-01-19 2017-07-27 Pfizer Inc. Vaccins anticancéreux
WO2018134693A1 (fr) 2017-01-20 2018-07-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2020039033A1 (fr) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Protéines et compositions immunogènes
WO2020039359A2 (fr) 2018-08-24 2020-02-27 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
US12156910B2 (en) 2018-11-16 2024-12-03 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
WO2020121159A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
WO2020170190A1 (fr) 2019-02-22 2020-08-27 Pfizer Inc. Procédés de purification de polysaccharides bactériens
WO2020208502A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués, kits les comprenant et leurs utilisations
WO2021084429A1 (fr) 2019-11-01 2021-05-06 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
NL2027383A (en) 2020-01-24 2021-09-01 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2021165847A1 (fr) 2020-02-21 2021-08-26 Pfizer Inc. Purification de saccharides
WO2021165928A2 (fr) 2020-02-23 2021-08-26 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
US12018063B2 (en) 2020-02-26 2024-06-25 Versitech Limited PD-1-based vaccines against coronavirus infection
WO2022090893A2 (fr) 2020-10-27 2022-05-05 Pfizer Inc. Compositions d'escherichia coli et procédés associés
WO2022097010A1 (fr) 2020-11-04 2022-05-12 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
WO2022101745A2 (fr) 2020-11-10 2022-05-19 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2022137078A1 (fr) 2020-12-23 2022-06-30 Pfizer Inc. Mutants fimh e. coli et leurs utilisations
WO2022147373A1 (fr) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
WO2022178196A1 (fr) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant méningococcique b
WO2022249107A2 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2022249106A2 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023092090A1 (fr) 2021-11-18 2023-05-25 Matrivax, Inc. Compositions de protéines de fusion immunogènes et leurs procédés d'utilisation
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024110839A2 (fr) 2022-11-22 2024-05-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
WO2024166008A1 (fr) 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024201324A2 (fr) 2023-03-30 2024-10-03 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
WO2024214016A1 (fr) 2023-04-14 2024-10-17 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées

Also Published As

Publication number Publication date
WO1997001640A3 (fr) 1997-05-15
CZ422397A3 (cs) 1998-06-17
NO976060L (no) 1998-02-17
PL324906A1 (en) 1998-06-22
TR199701713T1 (xx) 1998-05-21
WO1997001640A2 (fr) 1997-01-16
ZA965459B (en) 1997-04-01
KR19990028505A (ko) 1999-04-15
BR9609258A (pt) 1999-05-11
GB9513261D0 (en) 1995-09-06
HUP9901901A2 (hu) 1999-09-28
IL122589A0 (en) 1998-06-15
MX9710523A (es) 1998-09-30
CA2222456A1 (fr) 1997-01-16
HUP9901901A3 (en) 2000-03-28
AU6304996A (en) 1997-01-30
JPH11508769A (ja) 1999-08-03
NO976060D0 (no) 1997-12-23

Similar Documents

Publication Publication Date Title
EP0835318A2 (fr) Vaccins contre l'hepatite c
KR101350318B1 (ko) 보호 반응을 유도하는 댕기열 바이러스 캡시드 단백질 및약학적 조성물
EP1090033B1 (fr) Particules constituees de proteines d'enveloppe de vhc: utilisation pour la vaccination
US6680182B1 (en) Expression of recombinant fusion proteins in attenuated bacteria
CA2483653C (fr) Vaccin tetravalent contre la dengue contenant une suppression commune de 30 nucleotides dans la 3'-utr de types 1, 2, 3 et 4 de la dengue ou des virus antigenes chimeriquesde la dengue de types 1, 2, 3 et 4
US20070128213A1 (en) Novel plant virus particles and methods of inactivation thereof
JP2011521985A (ja) Ｈｃｖ感染の予防および治療のためのワクチン
CN114195884B (zh) 一种重组人源胶原蛋白及其制备方法
KR20110084906A (ko) 면역원-특이적 면역보강제로서의 재조합 단백질체들
CA2986342C (fr) Compositions immunogenes a base du virus de l'hepatite c et procedes d'utilisation
EP0191748B1 (fr) Vaccin contre le paludisme
EP0192626A1 (fr) Vaccin contre le paludisme
CN1189855A (zh) 抗丙型肝炎病毒的疫苗
DK2339011T3 (en) Chimeric of West Nile virus and dengue-4 virus for use in a live virus vaccine for the prevention of disease caused by the West Nile Virus
MXPA97010523A (en) Vaccines against hepatitis
US20100316669A1 (en) Vaccine formulation potentiated by the combination of dna and an antigen
CN100415891C (zh) 兔出血性疾病疫苗及抗原
KR102009266B1 (ko) 구제역 sat2형 zim의 방어항원이 발현되는 재조합 바이러스
KR102009267B1 (ko) 구제역 sat 3형 zim의 방어항원이 발현되는 재조합 바이러스
CN110684081A (zh) 一种编码分泌型多肽氨基酸的重组溶瘤新城疫病毒及其制备方法
CN110331148A (zh) 一种编码IFNα蛋白的基因、重组载体pELSH-IFNα、重组干酪乳杆菌及应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 971212

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

17Q First examination report despatched

Effective date: 20030602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031213

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1010212

Country of ref document: HK